肺癌中远程瘤学的特点:一个范围审查
Ali Garavand1, Nasim Aslani1, Ali Behmanesh2
1Department of Health Information Technology, School of Allied Medical Sciences, Lorestan University of Medical Sciences, Khorramabad, Iran.
Patient education and counseling
|June 9, 2023
概括
远程瘤学为肺癌护理挑战提供解决方案. 这次审查确定了关键特征,如症状监测和患者赋权,改善护理准入和结果.
科学领域:
- 在瘤学瘤学.
- 数字健康数字健康
- 医疗保健管理的管理
背景情况:
- 肺癌患者面临着重要的医疗保健接入挑战.
- 远程瘤学为克服这些障碍提供了一个可行的解决方案.
- 有效的实施对于改善患者的治疗结果至关重要.
研究的目的:
- 识别和分类肺癌患者的远程瘤干预的特点.
- 了解远程瘤学在肺癌治疗中的应用范围.
主要方法:
- 在2023年进行了全面的范围审查.
- 在2012-2023年期间搜索了主要的科学数据库 (PubMed,Scopus,Web of Science,Science Direct).
- 选了860篇文章,选择了39篇相关研究.
主要成果:
- 针对肺癌的远程瘤学干预包括四个主要类别:
- 1. 1. 1. 1. 这是一个很棒的节目. 症状监测 症状监测 症状监测
- 2. 2. 2. 这是一个很好的例子. 治疗和康复过程的监控,治疗和康复过程的监控.
- 3. 3. 3. 3. 这是一个很大的问题. 自主管理和患者赋权
- 4. 4. 4. 4. 这是一个很棒的节目. 患者咨询服务 患者咨询服务
结论:
- 适当的远程瘤实践可以改善患者的病情并减少并发症.
- 通过远程瘤学改善医疗服务的可用性是关键.
- 进一步的研究应侧重于患者和提供者的观点,并利用移动技术.
相关概念视频
Cancer Therapies
7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
lncRNA - Long Non-coding RNAs
8.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K


